Monoclonal antibody HNK20

Drug Profile

Monoclonal antibody HNK20

Alternative Names: Anti-RSV monoclonal antibody HNK20; HNK 20; MAb HNK20; Monoclonal IgA antibody HNK20

Latest Information Update: 23 Apr 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acambis
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Respiratory syncytial virus infections

Most Recent Events

  • 11 Dec 2000 OraVax is now called Acambis
  • 24 May 1999 OraVax acquired by Peptide Therapeutics
  • 20 Jun 1997 Data have been added to the therapeutic trials and adverse event sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top